Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2021 10:55 ET | Source: Biosplice Therapeutics, Inc.

Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform

New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...
December 01, 2020 10:00 ET | Source: Samumed, LLC.

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology

SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering therapeutics based on RNA alternative splicing for major diseases, announced today that...
June 01, 2020 11:00 ET | Source: Samumed, LLC.

Michael White, Ph.D. joins Samumed as Chief Scientific Officer

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced today that Dr. Michael White will...
May 22, 2020 09:00 ET | Source: Samumed, LLC.

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

SAN DIEGO, May 22, 2020 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of results from the Phase 2a trial of lorecivivint, an investigational CLK/DYRK1A inhibitor that modulates...